Aprea Therapeutics

Aprea Therapeutics announces an intellectual property portfolio of 28 granted patents and 30 pending applications. The WEE1 program, including the lead candidate APR-1051 (Phase-1 study ACESOT-1051), is covered by multiple US and non‑US filings; potential exclusivity could extend to 2047. The ATR program has issued US and non‑US patents and pending applications that, if granted, could provide protection through 2045. Aprea has deprioritized development of ATRN-119 as monotherapy in favor of APR-1051 and will instead evaluate ATRN-119 in combination therapies. » More on de.investing.com

Aprea Therapeutics will present data from the ongoing phase‑1 study ACESOT‑1051 of APR‑1051 at a scientific conference in Q4 2026. Dose escalation is currently in the 300 mg cohort (10–500 mg planned), and the number of active sites has been increased from three to ten, which is expected to raise the recruitment rate to six to ten patients per month by Q4 2026. The program will be expanded to include combinations with standard therapies in HPV‑positive head-and-neck squamous cell carcinoma and colorectal cancer; recruitment will also be expanded to at least 50 patients with serous endometrial carcinoma or cyclin‑E–overexpressing, platinum‑resistant ovarian cancer. Completion of dose escalation and the backfill expansion is expected in Q2 2027. » More on de.investing.com

At the annual meeting, Aprea Therapeutics shareholders voted to elect Marc Duey, Dr. Richard Peters and Dr. Bernd R. Seizinger to the board and to appoint EisnerAmper as auditor. They also approved a charter amendment allowing the board to effect a reverse stock split in a ratio of 1:3 to 1:8. The meeting authorized the possibility of adjourning the annual meeting and supported executive compensation in a non-binding vote. Aprea concurrently reported an oversubscribed private placement of USD 30 million and positive early study data for APR-1051; Oppenheimer rated the stock "Outperform." » More on de.investing.com